Daiichi Sankyo Taps Partners To Deepen China Olmesartan Penetration
This article was originally published in PharmAsia News
Daiichi Sankyo’s new alliances for olmesartan in China recognize the need to adapt to market diversity, as well as the huge potential for cardiovascular products in the country. The Japanese firm has teamed up with two domestic players to deepen the hypertension drug’s penetration as it faces its first loss of exclusivity elsewhere next year.
Register for our free email digests: